Clinical Trial Detail

NCT ID NCT03694834
Title Window of Opportunity Study of Pembrolizumab in Early Stage, High Grade Obesity-driven Endometrial Cancer
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

endometrial adenocarcinoma

uterine corpus serous adenocarcinoma

endometrial clear cell adenocarcinoma

Therapies

Pembrolizumab

Carboplatin + Paclitaxel + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.